Partnering with Regeneron is different. As one of the industry’s longest-standing and most successful biotech companies, we have stayed true to our science-driven roots while becoming a fully integrated biopharma company with global reach, a diverse product portfolio and resources that rival those of "big pharma." We fiercely cultivate and maintain our entrepreneurial culture, nimble decision-making ability and highly collaborative approach to science and drug development. Importantly, we will always prioritize investment in technology and innovation. Meet the team.
Get in touch to collaborate
“We look for partners who can complement and expand upon Regeneron's extensive in-house capabilities, strengthening our collective ability to address serious diseases and help people in need.”
Nouhad Husseini joined Regeneron in 2011 and serves as senior vice president, head of business development, overseeing the company’s efforts to execute new strategic collaborations and licensing agreements. He has nearly 20 years of experience in the biopharmaceutical industry, where he has held a variety of strategic, business development and finance roles, including in Genentech’s Business Development and Corporate Finance departments and in investment banking and equity research at Morgan Stanley and Robertson Stephens. Mr. Husseini received his undergraduate degree in molecular biology from Princeton University and MBA from the Wharton School at University of Pennsylvania.
"Our research collaborations are some of the most exciting in industry or academia. We love to come together to debate complex scientific concepts, identify program efficiencies and brainstorm what the future of medicine could look like."
Dr. Andrew Murphy joined Regeneron in 1999 as director of genomics and bioinformatics and is now executive vice president of research. In his time at the company, he has led the gene discovery and bioinformatics and target discovery groups. Dr. Murphy is a co-inventor of Regeneron's key technologies VelociGene® and VelocImmune® and continues to lead several technology centers and therapeutic focus areas. Prior to joining Regeneron, Dr. Murphy worked for seven years at Cadus Pharmaceuticals. He received his B.S. in molecular biology at the University of Wisconsin, and his Ph.D. in human genetics from Columbia University, College of Physicians and Surgeons.
We take great pride in our technology platforms that enhance and accelerate the full drug discovery and development continuum. Whether it is developing new methods to support the world's most ambitious effort in human genetic sequencing, leading the way in antibody discovery and engineering with VelociSuite®, building world-leading biologics production capabilities, or investigating novel genetics medicine approaches, our platforms and expertise bring unique value to our collaborations and collaborators.
The Regeneron Genetics Center® (RGC®) is one of the most comprehensive and actionable genetic databases in the world.
Our proven, proprietary technology platform VelociSuite® accelerates, improves and disrupts the traditional drug development process.
The Industrial Operations and Product Supply (IOPS) team is responsible for the production of Regeneron products.
Our product portfolio and investigational pipeline are powered by end-to-end research and development capabilities.
The best work happens when we find synergies between emerging innovation from external partners and our own science and technology.
Our strategy is simple: Follow the science. The next game-changing innovation could be relevant for any therapeutic area, and we go wherever the most promising research may take us.
licensing and collaboration agreements and other significant Business Development transactions over the past five years
Gene Editing / Viral and Non-Viral Gene Therapies / Cell Therapies / RNAi / mRNA / Vaccines Technologies and more
Ophthalmology / Hematology / Oncology / Immunology & Inflammation / Cardiovascular and Metabolic Diseases / Infectious Disease
We are open to collaborations representing true scientific and technological advances that benefit patients, regardless of therapeutic area. Our unique approach leverages the expertise of our collaborators by combining Regeneron’s own homegrown technologies and innovations to take drug development to the next level.
For example, we consider:
The best work happens when we find synergies between emerging innovation from external partners and our own science and technology. We are holistic partners committed to the success of our collaborations. From start to end, our tenured research & development and commercial leaders are deeply engaged in collaborations and our strategic alliances team serves as a champion and true business partner.
Since 2020, Regeneron and BioNTech have nurtured a growing collaboration exploring synergistic immuno-oncology treatment combinations for several cancer types. The companies are advancing the clinical development of Regeneron’s homegrown PD-1 inhibitor, in combination with BioNTech’s investigational FixVac mRNA vaccine candidate for the potential treatment of several high-unmet-need oncology indications. In addition, our most recent agreement offers BioNTech the enhanced ability to pair our PD-1 inhibitor broadly across their investigational portfolio.
“Collaborating with an innovative company like BioNTech enables us to investigate and pioneer novel approaches that could one day lead to additional treatments to help more people with cancer,” said Lucy Kappel, Vice President, Business Development at Regeneron. “In addition, this collaboration builds on and complements our own efforts to find solutions for many difficult-to-treat cancer types.”
Our PD-1 inhibitor is the cornerstone of our oncology portfolio and identification of novel combinations is a priority for Regeneron. Beyond our collaboration with BioNTech, there are more than a dozen active supply and clinical collaborations for this treatment, and we continue to seek ways to expand and complement Regeneron’s extensive in-house efforts to develop innovative combination approaches to treat cancer.
Regeneron and Intellia Therapeutics, Inc. are working together to advance potentially groundbreaking applications of CRISPR/Cas9 technology to address genetic diseases. CRISPR/Cas9 therapy holds promise to potentially cure disease with a single dose by selectively inactivating disease-causing genes (the “knock-out” approach) and/or restoring necessary genetic functions by targeted insertion of a functional DNA sequence into the genome of patients deficient in an essential gene (the “knock-in” approach).
"Regeneron and Intellia are working hard to find safe and innovative solutions to rare genetic diseases. We believe the precise CRISPR/Cas9 in vivo gene editing therapeutics jointly developed with Intellia could yield great advances in many diseases where significant unmet needs currently exist," said David Gutstein, MD, Vice President, Global Program Head at Regeneron.
In the early days of the pandemic, Roche and Regeneron came together to develop, manufacture and distribute Regeneron’s investigational monoclonal antibody cocktail to treat and prevent COVID-19 to as many people as possible in record time.
While successfully completing the clinical development program, Regeneron and Roche moved swiftly to start producing the medicine at manufacturing sites around the globe — a herculean effort to increase the supply and reach more patients at a crucial and devastating time during the pandemic. The Roche collaboration more than tripled manufacturing capacity, and ultimately millions of doses of the antibody cocktail were supplied around the world.
"This major collaboration with Roche provided important scale in record time, enabling our medicine to reach millions of patients in the United States and around the globe. Together, we delivered when the world needed it most and provided an important option for those suffering from, or at high-risk for, COVID-19," said Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances at Regeneron.
In an example of a commercial-stage agreement, Regeneron granted Kiniksa Pharmaceuticals Ltd. an exclusive license to develop and commercialize our anti-inflammatory treatment in many countries around the world. As Regeneron’s very first therapy to enter the market, this treatment is an interleukin-1 (IL-1) blocker first approved in 2008. Since entering into the licensing agreement in 2017, Kiniksa has led the evaluation of this treatment in diseases believed to be mediated by both IL-1α and IL-1β. Our treatment is now being commercialized in multiple indications.
“As our first FDA-approved treatment, our IL-1 blocker exemplifies Regeneron’s commitment to discover and develop important medicines for patients with serious diseases, whether they are highly prevalent or ultrarare,” said Scott Mellis, Vice President, Early Clinical Development and Experimental Sciences, Rare Disease, at Regeneron. “Our agreement with Kiniksa has enabled expansion of approved indications so that this important medication can help many of those affected by IL-1-driven disease.”
Regeneron believes that academic and research institutions can further extend the impact of our science, technology and medicine. We provide access to our tools, investigational candidates and approved medicines to partners who are seeking deeper biologic knowledge and new ways to improve patient care.
We welcome the opportunity to discuss academic and research collaborations in the following areas:
Licensing and collaboration opportunities
Submit an inquiry if you are a business development executive interested in licensing and collaboration opportunities.
Third-party clinical research
Visit the third-party research requests portal if you are a third-party investigator or clinician seeking funding for:
Preclinical research collaborations
Visit the preclinical collaborations portal if you are an academic or research institution interested in discussing nonclinical research collaborations.
Genetics research collaborations
If you are interested in collaborations in genetic research.
